Celltrion applies approval of antibody biosimilar ‘Herzuma’ to EMA

On the 27^th of October(local time), Celltrion announced the application for approval of the antibody biosimilar to treat breast cancer, ‘Herzuma,’ was officially accepted at the European Medicines Agency(EMA). The original product of Herzuma is the U.S. Roche’s antibody, ‘Herceptin(generic name: trastuzumab),’ which annually records KRW 7 trillion sales.

Celltrion has already acquired approval...